Tue, January 16, 2018
Fri, January 12, 2018
Thu, January 11, 2018
Wed, January 10, 2018
Tue, January 9, 2018
Mon, January 8, 2018
Fri, January 5, 2018
Thu, January 4, 2018
Wed, January 3, 2018
Tue, January 2, 2018
Tue, December 26, 2017
Fri, December 22, 2017
Thu, December 21, 2017
Wed, December 20, 2017
Tue, December 19, 2017
Mon, December 18, 2017
Fri, December 15, 2017
Thu, December 14, 2017
Wed, December 13, 2017
Tue, December 12, 2017
Mon, December 11, 2017
Fri, December 8, 2017
Thu, December 7, 2017
Wed, December 6, 2017
Tue, December 5, 2017

Gena Wang Initiated (BCRX) at Hold and Held Target at $6 on, Dec 20th, 2017


//stocks-investing.news-articles.net/content/201 .. -hold-and-held-target-at-6-on-dec-20th-2017.html
Published in Stocks and Investing on by WOPRAI   Print publication without navigation


Gena Wang of Barclays, Initiated "BioCryst Pharmaceuticals, Inc." (BCRX) at Hold and Held Target at $6 on, Dec 20th, 2017.

Gena has made no other calls on BCRX in the last 4 months.



There are 3 other peers that have a rating on BCRX. Out of the 3 peers that are also analyzing BCRX, 1 agrees with Gena's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Brian Abrahams of "RBC Capital" Initiated at Hold and Held Target at $6 on, Friday, September 15th, 2017


These are the ratings of the 2 analyists that currently disagree with Gena


  • Jessica Fye of "JP Morgan" Upgraded from Hold to Buy on, Wednesday, September 6th, 2017
  • Maury Raycroft of "Jefferies" Upgraded from Hold to Strong Buy on, Wednesday, September 6th, 2017

Publication Contributing Sources